Fate Therapeutics (FATE) 10-Q 7 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 06, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	FATE THERAPEUTICS INC
Entity Central Index Key	0001434316
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Trading Symbol	FATE
Entity Common Stock, Shares Outstanding		65,185,834
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 183,033	$ 190,514
Accounts receivable	500	500
Short-term investments and related maturity receivables		10,493
Prepaid expenses and other current assets	2,897	3,689
Total current assets	186,430	205,196
Property and equipment, net	8,402	5,125
Operating lease right-of-use assets, net	23,955
Restricted cash	227	227
Collaboration contract asset	1,851	1,958
Other assets		526
Total assets	220,865	213,032
Current liabilities:
Accounts payable	5,367	4,205
Accrued expenses	9,950	10,926
CIRM award liability, current portion	2,106	2,106
Deferred revenue, current portion	6,576	7,588
Operating lease liabilities, current portion	1,200
Long-term debt, current portion	3,941	2,438
Total current liabilities	29,140	27,263
Deferred rent		3,401
Accrued expenses	629	549
Deferred revenue, net of current portion	6,380	7,500
CIRM award liability, net of current portion	1,404	1,404
Operating lease liabilities, net of current portion	26,517
Long-term debt, net of current portion	10,958	12,446
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized shares—5,000,000 at March 31, 2019 and December 31, 2018; 2,819,549 Class A Convertible Preferred shares issued and outstanding at March 31, 2019 and December 31, 2018	3	3
Common stock, $0.001 par value; authorized shares—150,000,000 at March 31, 2019 and December 31, 2018; issued and outstanding—65,115,846 at March 31, 2019 and 64,693,681 at December 31, 2018	65	65
Additional paid-in capital	450,925	445,799
Accumulated other comprehensive loss		(2)
Accumulated deficit	(305,156)	(285,396)
Total stockholders’ equity	145,837	160,469
Total liabilities and stockholders’ equity	$ 220,865	$ 213,032

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	150,000,000	150,000,000
Common stock issued	65,115,846	64,693,681
Common stock, outstanding shares	65,115,846	64,693,681
Class A Convertible Preferred Shares
Preferred stock, issued shares	2,819,549	2,819,549
Preferred stock, outstanding shares	2,819,549	2,819,549

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Collaboration revenue	$ 2,632	$ 1,026
Type of Revenue [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 17,728	$ 11,476
General and administrative	5,350	3,604
Total operating expenses	23,078	15,080
Loss from operations	(20,446)	(14,054)
Other income (expense):
Interest income	1,091	331
Interest expense	(405)	(412)
Total other income (expense), net	686	(81)
Net loss	(19,760)	(14,135)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities, net	2	(10)
Comprehensive loss	$ (19,758)	$ (14,145)
Net loss per common share, basic and diluted	$ (0.30)	$ (0.27)
Weighted-average common shares used to compute basic and diluted net loss per share	64,920,621	52,763,306

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities
Net loss	$ (19,760)	$ (14,135)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	440	286
Stock-based compensation	3,868	1,382
Amortization of debt discounts and debt issuance costs	15	19
Amortization of premiums and discounts on investments, net	(5)	(75)
Amortization of collaboration contract asset	107
Noncash interest expense	79	92
Deferred rent		69
Deferred revenue	(2,132)	(526)
Changes in operating assets and liabilities:
Accounts receivable		(500)
Prepaid expenses and other assets	792	164
Accounts payable and accrued expenses	(1,258)	673
Right-of-use assets and lease liabilities, net	361
Net cash used in operating activities	(17,493)	(12,551)
Investing activities
Purchases of property and equipment	(1,746)	(184)
Purchases of short-term investments		(55,660)
Maturities of short-term investments	10,500	12,000
Net cash provided by (used in) investing activities	8,754	(43,844)
Financing activities
Issuance of common stock from equity incentive plans, net of issuance costs	1,258	606
Issuance costs from public offering of common stock		(251)
Net cash provided by financing activities	1,258	355
Net change in cash, cash equivalents and restricted cash	(7,481)	(56,040)
Cash, cash equivalents and restricted cash at beginning of the period	190,741	89,074
Cash, cash equivalents and restricted cash at end of the period	183,260	33,034
Supplemental disclosure of cash flow information
Interest paid	309	299
Supplemental schedule of noncash investing and financing activities
Purchases of property and equipment in accounts payable	$ 1,482	$ 257

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Organization Fate Therapeutics, Inc. (the Company) was incorporated in the state of Delaware on April 27, 2007 and has its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master induced pluripotent stem cell (iPSC) lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adaptive cell therapy programs are based on the Company’s novel ex vivo As of March 31, 2019, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated any revenues from any sales of its therapeutic products. To date, the Company’s revenues have been derived from collaboration agreements and government grants. Public Equity Offerings In September 2018, the Company completed a public offering of common stock in which investors, certain of which are affiliated with the directors of the Company, purchased 10,648,149 shares of its common stock at a price of $13.50 per share under a shelf registration statement. Gross proceeds from the offering were $143.8 million, and, after giving effect to $8.9 million of costs related to the offering, net proceeds were $134.9 million. In December 2017, the Company completed a public offering of common stock in which investors purchased 10,953,750 shares of its common stock at a price of $4.20 per share under a shelf registration statement. Gross proceeds from the offering were $46.0 million, and, after giving effect to $3.0 million of costs related to the offering (of which $0.3 million was paid during the three months ended March 31, 2018), net proceeds were $43.0 million. Use of Estimates The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Therapeutics Ltd., incorporated in the United Kingdom, Fate Therapeutics, B.V., incorporated in the Netherlands, and Tfinity Therapeutics, Inc., incorporated in the United States. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amount shown in the unaudited condensed consolidated statements of cash flows as of March 31, 2019 (in thousands): Three Months Ended March 31, 2019 Cash and cash equivalents $ 183,033 Restricted cash 227 Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statement of cash flows $ 183,260 Amounts included in restricted cash represent security deposits required to secure the Company’s credit card limit and its facilities lease. Investments Investments are accounted for as available-for-sale securities and are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of investments classified as available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on investments classified as available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. The interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements and accompanying notes for the fiscal year ended December 31, 2018, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed by the Company with the SEC on March 5, 2019. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position and its results of operations and comprehensive loss and its cash flows for the periods presented. The results for the three months ended March 31, 2019 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period. Revenue Recognition The Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. A customer is a party that has entered into a contract with the Company, where the purpose of the contract is to obtain a product or a service that is an output of the Company’s ordinary activities in exchange for consideration. To be considered a contract, (i) the contract must be approved (in writing, orally, or in accordance with other customary business practices), (ii) each party’s rights regarding the product product product A performance obligation is defined as a promise to transfer a product The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation in an amount that reflects the consideration the Company is entitled to receive in exchange for satisfying each distinct performance obligation. For each distinct performance obligation, revenue is recognized when (or as) the Company transfers control of the product or the service applicable to such performance obligation. In those instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until (or as) the Company satisfies such performance obligation. In those instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is recorded as accounts receivable. The Company expenses incremental costs of obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract. Leases Effective January 1, 2019, the Company determines if a contract contains a lease at the inception of the contract. The Company currently has leases related to its facilities leased for office and laboratory space, which are classified as operating leases. These leases result in operating right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities in the condensed consolidated balance sheets. The Company does not have any financing leases. Leases with a term of 12 months or less are considered short-term and a ROU asset and lease obligation are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term. ROU assets represent the right to use an underlying asset for the lease term and the lease liabilities represent an obligation to make lease payments arising from the lease, measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the life of the lease term. To determine the present value, the implicit rate is used when readily determinable. For those leases where the implicit rate is not provided, the Company determines an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The operating lease ROU assets also include any prepaid lease payments made and any other indirect costs and excludes any lease incentives received. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company aggregates all lease and non-lease components for each class of underlying assets into a single lease component . Stock-Based Compensation Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model. The fair value of restricted stock units is based on the closing price of the Company’s common stock as reported on The Nasdaq Global Market on the date of grant. The Company recognizes forfeitures for all awards as such forfeitures occur. Convertible Preferred Stock The Company applies the relevant accounting standards to distinguish liabilities from equity when assessing the classification and measurement of preferred stock. Preferred shares subject to mandatory redemptions are considered liabilities and measured at fair value. Conditionally redeemable preferred shares are considered temporary equity. All other preferred shares are considered as stockholders’ equity. The Company applies the relevant accounting standards for derivatives and hedging (in addition to distinguishing liabilities from equity) when accounting for hybrid contracts that contain conversion options. Conversion options must be bifurcated from the host instruments and accounted for as free-standing financial instruments according to certain criteria. These criteria include circumstances when (i) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable accounting principles with changes in fair value reported in earnings as they occurred, and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently measured at fair value at each reporting date, with the changes in fair value reported in earnings. Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non‑owner sources. Other comprehensive loss includes unrealized gains and losses on investments classified as available-for-sale securities, which was the only difference between net loss and comprehensive loss for the applicable periods. Net Loss per Common Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Dilutive common stock equivalents for the periods presented include convertible preferred stock, warrants for the purchase of common stock, and common stock options and restricted stock units outstanding under the Company’s stock option and incentive plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. For the three months ended March 31, 2019, the Company realized a net loss of $19.8 million. Shares of potentially dilutive securities totaled 23.9 million for the three months ended March 31, 2019, including 14.1 million shares associated with a hypothetical conversion of all outstanding shares of the Company’s Class A convertible preferred stock, and an aggregate of 9.7 million shares of common stock issuable upon the exercise of outstanding stock options and the settlement of outstanding restricted stock units. For the three months ended March 31, 2018, the Company realized a net loss of $14.1 million. Shares of potentially dilutive securities totaled 22.0 million for the three months ended March 31, 2018, including 14.1 million shares associated with a hypothetical conversion of all outstanding shares of the Company’s Class A convertible preferred stock, and an aggregate of 7.7 million shares of common stock issuable upon the exercise of outstanding stock options and the settlement of outstanding restricted stock units. Going Concern Assessment Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements. Recently Adopted Accounting Pronouncements In June 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07. ASU 2018-07 expands the scope of Accounting Standards Codification (ASC) 718, Compensation- Stock Compensation, In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) The Company adopted the standard effective January 1, 2019 using the optional transition method as detailed in ASU 2018-11, which resulted in an increase in operating right-of-use assets of $16.6 million and an increase in total liabilities of $18.2 million on the unaudited condensed consolidated balance sheet as of the effective date. There was not a material impact to the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2019 as a result of the adoption of ASU 2016-02. There was no impact to the unaudited condensed consolidated financial statements for the prior periods presented due to the transition method elected. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed the Company to carry forward the historical lease classification. Additionally, the Company elected the hindsight provision for determining the lease term and elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component. Recently Issued Accounting Pronouncements In November 2018, the FASB issued ASU 2018-18, which clarifies the interaction between ASC Topic 808, Collaborative Arrangements Revenue from Contracts with Customers In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments In August 2018, the FASB issued ASU No. 2018-13 (ASU 2018-13). ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, amends the disclosure requirements in 820 by adding, changing, or removing certain disclosures. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. The Company believes that the adoption of this guidance will not have a material impact on the Company’s consolidated financial statements.

Collaboration and License Agree

Collaboration and License Agreements	3 Months Ended
	Mar. 31, 2019
Collaboration And License Agreements Disclosure [Abstract]
Collaboration and License Agreements	2. Collaboration and License Agreements Ono Collaboration and Option Agreement On September 14, 2018, the Company entered into a Collaboration and Option Agreement (the Ono Agreement) with Ono Pharmaceutical Co. Ltd. (Ono) for the joint development and commercialization of two off-the-shelf iPSC-derived chimeric antigen receptor (CAR) T-cell product candidates. The first off-the-shelf, iPSC-derived CAR T-cell candidate (Candidate 1) targets an antigen expressed on certain lymphoblastic leukemias, and the second off-the-shelf, iPSC-derived CAR T-cell candidate (Candidate 2) targets a novel antigen identified by Ono expressed on certain solid tumors (each a Candidate and collectively the Candidates). Pursuant to the Ono Agreement, the Company and Ono are jointly conducting research and development activities under a joint development plan, with the goal of advancing each Candidate to a pre-defined preclinical milestone. The Company has granted to Ono, during a specified period of time, an option to obtain an exclusive license under certain intellectual property rights to develop and commercialize (a) Candidate 1 in Asia, with the Company retaining rights for development and commercialization in all other territories of the world and (b) Candidate 2 in all territories of the world, with the Company retaining the right to co-develop and co-commercialize Candidate 2 in the United States and Europe under a joint arrangement whereby it is eligible to share at least 50% of the profits and losses (each, an Option). For each Candidate, the Option will expire upon the earliest of: (a) the achievement of the pre-defined preclinical milestone, (b) termination by Ono of research and development activities for the Candidate and (c) the date that is the later of (i) four years after the Effective Date and (ii) completion of all applicable activities contemplated under the joint development plan (the Option Period). The Company has maintained worldwide rights of manufacture for both Candidates. Under the terms of the Ono Agreement, Ono paid the Company an upfront, non-refundable and non-creditable payment of $10.0 million in connection with entering into the Ono Agreement. Additionally, as consideration for the Company’s conduct of research and preclinical development under a joint development plan, Ono pays the Company annual research and development fees set forth in the annual budget included in the joint development plan, which fees are estimated to be $20.0 million in aggregate over the course of the joint development plan. The Company received $5.0 million in October 2018 as a prepayment for the first year of research and development. Further, under the terms of the Ono Agreement, Ono has agreed to pay the Company up to an additional $40.0 million, subject to the achievement of a preclinical milestone (Option Milestone) and the exercise by Ono of the Options (Option Exercise Fees) during the Option Period. Such fees are in addition to the upfront payment and research and development fees. Subject to Ono’s exercise of the Options and to the achievement of certain clinical, regulatory and commercial milestones (Milestones) with respect to each Candidate in specified territories, the Company is entitled to receive an aggregate of up to $285.0 million in milestone payments for Candidate 1 and an aggregate of up to $895.0 million in milestone payments for Candidate 2, with the applicable milestone payments for Candidate 2 for the United States and Europe subject to reduction by 50% if the Company elects to co-develop and co-commercialize Candidate 2 as described above. The Company is also eligible to receive tiered royalties (Royalties) ranging from the mid-single digits to the low-double digits based on annual net sales by Ono of each Candidate in specified territories, with such royalties subject to certain reductions. The Ono Agreement will terminate with respect to a Candidate if Ono does not exercise its Option for a Candidate within the Option Period, or in its entirety if Ono does not exercise any of its Options for the Candidates within their respective Option Periods. In addition, either party may terminate the Ono Agreement in the event of breach, insolvency or patent challenges by the other party; provided, that Ono may terminate the Ono Agreement in its sole discretion (x) on a Candidate-by-Candidate basis at any time after the second anniversary of the effective date of the Ono Agreement or (y) on a Candidate-by-Candidate or country-by-country basis at any time after the expiration of the Option Period, subject to certain limitations. The Ono Agreement will expire on a Candidate-by-Candidate and country-by-country basis upon the expiration of the applicable royalty term, or in its entirety upon the expiration of all applicable payment obligations under the Ono Agreement. The Company applied ASC 808, Collaborative Arrangements Revenue from Contracts with Customers The Company also assessed, in connection with the upfront, non-refundable and non-creditable payment of $10.0 million received in September 2018 and the $5.0 million prepayment of the first-year research and development fees in October 2018, whether a significant financing component exists under the Ono Agreement. Such assessment evaluated whether: (i) a substantial amount of the consideration is variable, (ii) the amount, or timing of payment, of the consideration would have varied based on the occurrence or non-occurrence of future events that are not substantially within the control of the Company or Ono, and (iii) the timing of the transfer of the performance obligations is at the discretion of Ono. Based on its assessment, the Company concluded that there was not a significant financing component. The Company also assessed the effects of any variable elements under the Ono Agreement. Such assessment evaluated, among other things, the likelihood of receiving (i) preclinical milestone and option fees, (ii) various clinical, regulatory and commercial milestone payments, and (iii) royalties on net sales of either product Candidate. Based on its assessment, the Company concluded that, based on the likelihood of these variable components occurring, there was not a significant variable element included in the transaction price. In accordance with ASC 606, the Company determined that the initial transaction price under the Ono Agreement equals $30.0 million, consisting of the upfront, non-refundable and non-creditable payment of $10.0 million and the aggregate estimated research and development fees of $20.0 million. The upfront payment of $10.0 million was recorded as deferred revenue and is being recognized as revenue over time in conjunction with the Company’s conduct of research services over the estimated four-year period based on actual costs incurred compared to the estimated total costs expected to be incurred under the Ono Agreement, as the research and development activities are the primary component of the combined performance obligation. The Company recorded the $5.0 million prepayment of the first-year research and development fees as deferred revenue, and such fees are recognized as revenue as the research services are delivered. The Company has not assigned a transaction price to any Option Milestone, Milestones or Option Exercise Fees given the substantial uncertainty related to their achievement and has not assigned a transaction price to any Royalties. As a direct result of the Company’s entry into the Ono Agreement, the Company incurred an aggregate of $2.0 million in sublicense consideration to existing licensors of the Company. The $2.0 million in sublicense consideration represents an asset under ASC 340, Other Assets and Deferred Costs The Company recognized revenue of $1.6 million under the Ono Agreement for the three months ended March 31, 2019. Such revenue was comprised of $1.1 million associated with research services and $0.5 million associated with the upfront payment. As of March 31, 2019, aggregate deferred revenue related to the Ono Agreement was $12.8 million, of which $6.4 million is classified as current. Juno Collaboration and License Agreement On May 4, 2015, the Company entered into a strategic research collaboration and license agreement (the Juno Agreement) with Juno Therapeutics, Inc. (Juno) to screen for and identify small molecules that enhance the therapeutic properties of Juno’s genetically-engineered T-cell immunotherapies. The four-year initial research term under the Juno Agreement concluded as scheduled on May 4, 2019, and accordingly, the Company expects the overall agreement to terminate upon the receipt of the last quarterly research payment of $0.2 million. Aside from this last quarterly research payment, no additional funding is expected from Juno. The Company applied ASC 606 to evaluate the appropriate accounting for the Juno Agreement. In accordance with this guidance, the Company identified its performance obligations, including its grant of an exclusive worldwide license to certain of its intellectual property subject to certain conditions, its conduct of research services and its participation in a joint research committee. Total revenue recognized under the Juno Agreement for both the three months ended March 31, 2019 and 2018 was $1.0 million. Such revenue for each period presented included $0.5 million associated with the upfront fee and an equity premium, and $0.5 million associated with research services. As of March 31, 2019, aggregate deferred revenue related to the Juno Agreement was $0.2 million, all of which is classified as current. As of March 31, 2019, accounts receivable related to the Juno Agreement was $0.5 million, which amount was received in April 2019. Memorial Sloan Kettering Cancer Center License Agreement On May 15, 2018, the Company entered into an Amended and Restated Exclusive License Agreement (the Amended MSK License) with Memorial Sloan Kettering Cancer Center (MSK). The Amended MSK License amends and restates the Exclusive License Agreement entered into between the Company and MSK on August 19, 2016 (the Original MSK License), pursuant to which the Company entered into an exclusive license agreement with MSK for rights relating to compositions and methods covering iPSC-derived cellular immunotherapy, including T-cells and NK-cells derived from iPSCs engineered with CARs. Pursuant to the Amended MSK License, MSK granted to the Company additional licenses to certain patents and patent applications relating to new CAR constructs and off-the-shelf CAR T cells, including the use of clustered regularly interspaced short palindromic repeat (CRISPR) and other innovative technologies for their production, in each case to research, develop, and commercialize licensed products in the field of all human therapeutic uses worldwide. The Company has the right to grant sublicenses to certain licensed rights in accordance with the terms of the Amended MSK License, in which case it is obligated to pay MSK a percentage of certain sublicense income received by the Company. The Company issued 500,000 shares of the Company’s common stock to MSK (the MSK Shares), and, in return, MSK returned its entire interest in Tfinity Therapeutics, Inc. (Tfinity) to the Company. As a result, as of the effective date of the Amended MSK License, Tfinity is a wholly-owned subsidiary of the Company. The MSK Shares were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended (the Securities Act), in reliance on Section 4(a)(2) of the Securities Act regarding transactions by an issuer not involving a public offering. Additionally, the Company paid an upfront fee of $0.5 million. The Company is also obligated to pay to MSK an annual license maintenance fee during the term of the agreement, and milestone payments upon the achievement of specified clinical, regulatory and commercial milestones for licensed products as well as royalty payments on net sales of licensed products. Furthermore, in the event a licensed product achieves a specified clinical milestone, MSK is then eligible to receive additional milestone payments, where the amount of such payments owed to MSK contingent upon certain increases in the price of the Company’s common stock relative to the price of the common stock following the date of achievement of such clinical milestone. Given the high degree of uncertainty surrounding the achievement of clinical milestones and the requisite increase in the price of the Company’s common stock, the Company has not recorded a liability for such payments. Upon initiation of the contract, the Company recognized an aggregate of $5.3 million of research and development expenses, consisting of the $0.5 million upfront cash payment to MSK and the issuance of the MSK Shares, valued at $4.8 million, associated with the Amended MSK License. Gladstone License Agreement On September 11, 2018, the Company entered into an exclusive license agreement (the Gladstone License Agreement) with the J. David Gladstone Institutes (Gladstone). Pursuant to the Gladstone License Agreement, Gladstone granted to the Company exclusive licenses to certain patents and patent applications (the Patent Rights) for the research, development, manufacturing, and commercialization of human therapeutics derived from iPSCs. The Patent Rights cover the use of the CRISPR and engineered nuclease-deactivated CRISPR-associated protein-9 (dCas9) system, known as the CRISPR activation (CRISPRa) system, for cellular reprogramming and iPSC generation. In consideration for the rights granted under the Gladstone License Agreement, the Company issued to Gladstone 100,000 shares of the Company’s common stock (the Gladstone Shares). The Gladstone Shares were issued pursuant to an exemption from registration under the Securities Act, in reliance on Section 4(a)(2) of the Securities Act regarding transactions by an issuer not involving a public offering. Additionally, the Company paid Gladstone an upfront fee of $0.1 million and is obligated to pay Gladstone milestone payments in an aggregate amount of up to approximately $1.9 million upon the achievement of specified clinical, regulatory and commercial milestones as well as tiered royalties in the low single digits on net sales of human therapeutic products covered by the Patent Rights. The Company is also obligated to pay Gladstone a tiered percentage in the low- to mid-single digits of certain income received by the Company in connection with the sublicense of the licensed Patent Rights. Upon initiation of the contract, the Company recognized an aggregate of $1.4 million of research and development expenses, consisting of the $0.1 million upfront cash payment to Gladstone and the issuance of the Gladstone Shares, valued at $1.3 million, associated with the Gladstone License Agreement.

California Institute for Regene

California Institute for Regenerative Medicine Award	3 Months Ended
	Mar. 31, 2019
Award From Regenerative Medicine Institute [Abstract]
California Institute for Regenerative Medicine Award	3. California Institute for Regenerative Medicine Award On April 5, 2018, the Company executed an award agreement with the California Institute for Regenerative Medicine (CIRM) pursuant to which CIRM awarded the Company $4.0 million to advance the Company’s FT516 product candidate into a first-in-human clinical trial for the treatment of subjects with advanced solid tumors, including in combination with monoclonal antibody therapy (the Award). Pursuant to the terms of the Award, the Company is eligible to receive five disbursements in varying amounts totaling $4.0 million, with one disbursement receivable upon the execution of the Award, and four disbursements receivable upon the completion of certain milestones throughout the project period, which is estimated to be from April 1, 2018, to June 30, 2019 (the Project Period). The Award is subject to certain co-funding requirements by the Company, and the Company is required to provide CIRM progress and financial update reports throughout the Project Period. In December 2018, the Company discussed with CIRM its intent to pursue the clinical development of FT516 in relapsed / refractory hematologic malignancies in addition to advanced solid tumors, and the Company’s preference to first submit an IND application for FT516 in relapsed / refractory hematologic malignancies rather than in advanced solid tumors. In January 2019, the Company submitted its IND application for FT516 in relapsed / refractory hematologic malignancies, which IND submission was allowed by the FDA in February 2019. The Company and CIRM have agreed to suspend the Award until such time as the Company submits an IND application for FT516 in advanced solid tumors. The Company has notified CIRM of its intent to do so. At the time of suspension, an additional $0.5 million was available for funding under the Award. Pursuant to the terms of the Award, the Company, in its sole discretion, has the option to treat the Award either as a loan or as a grant. In the event the Company elects to treat the Award as a loan, the Company will be obligated to repay i) 60%, ii) 80%, iii) 100% or iv) 100% plus interest at 7% plus LIBOR, of the total Award to CIRM, where such repayment rate is dependent upon the phase of clinical development of FT516 at the time of the Company’s election. If the Company does not elect to treat the Award as a loan within 10 years of the date of the Award, the Award will be considered a grant and the Company will be obligated to pay to CIRM a royalty on commercial sales of FT516 until such royalty payments equal nine times the total amount awarded to the Company under the Award. Since the Company may, at its election, repay some or all of the Award, the Company accounts for the Award as a liability until the time of election. As of March 31, 2019, the Company has received aggregate disbursements under the Award in the amount of $3.5 million. The aggregate amount received is recorded as a CIRM Liability on the accompanying unaudited condensed consolidated balance sheets and classified as current or non-current based on the potential amount payable within twelve months of the current balance sheet.

Investments

Investments	3 Months Ended
	Mar. 31, 2019
Short Term Investments [Abstract]
Investments	4. Investments The Company invests portions of excess cash in United States treasuries with maturities ranging from three to twelve months from the purchase date. These debt securities are classified as short-term investments in the accompanying unaudited condensed consolidated balance sheets based on the maturity date and are accounted for as available-for-sale securities. The Company did not have any investments as of March 31, 2019. The following table summarizes the Company’s investments accounted for as available-for-sale securities as of December 31, 2018 (in thousands): Maturity (in years) Amortized Cost Unrealized Losses Unrealized Gains Estimated Fair Value December 31, 2018 U.S. Treasury debt securities 1 or less 10,495 (2 ) — 10,493 Total $ 10,495 $ (2 ) $ — $ 10,493 The Company reviews its investment holdings at the end of each reporting period, and historically determined that any unrealized losses were not other-than-temporary unrealized losses because the Company did not intend to sell the underlying securities prior to maturity and it was not more likely than not that the Company would be required to sell these securities before the recovery of their amortized cost basis. During each of the three months ended March 31, 2019 and 2018, the Company did not recognize any impairment or realized gains or losses on sales of investments classified as available-for-sale securities.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value. The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Financial assets measured at fair value on a recurring basis consist of the Company’s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and short-term investments consisted of U.S. treasuries. The following table presents the Company’s assets which were measured at fair value on a recurring basis as of March 31, 2019 and December 31, 2018 (in thousands): Fair Value Measurements at Reporting Date Using Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) As of March 31, 2019: Cash equivalents $ 183,033 $ 183,033 $ — $ — Total $ 183,033 $ 183,033 $ — $ — As of December 31, 2018: Cash equivalents $ 190,514 $ 190,514 $ — $ — U.S. Treasury debt securities 10,493 10,493 — — Total $ 201,007 $ 201,007 $ — $ — The Company obtains pricing information from quoted market prices from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. As of March 31, 2019, and December 31, 2018, the Company had no material financial liabilities measured at fair value on a recurring basis.

Accrued Expenses and Long-Term

Accrued Expenses and Long-Term Debt	3 Months Ended
	Mar. 31, 2019
Accrued Expenses And Long Term Debt Disclosure [Abstract]
Accrued Expenses and Long-Term Debt	6. Accrued Expenses and Long-Term Debt Accrued Expenses Current accrued expenses consist of the following (in thousands): March 31, 2019 December 31, 2018 Accrued payroll and other employee benefits $ 1,901 $ 2,938 Accrued clinical trial related costs 4,462 4,729 Accrued other 3,587 3,259 Current accrued expenses $ 9,950 $ 10,926 Long-term accrued expenses consist of accruals for the final payment fees associated with the Company’s long-term debt. Long-Term Debt Long-term debt and unamortized discount balances are as follows (in thousands): March 31, 2019 December 31, 2018 Long-term debt $ 15,000 $ 15,000 Less debt issuance costs and discount, net of current portion (42 ) (54 ) Long-term debt, net of long-term portion of debt issuance costs and discount 14,958 14,946 Less current portion of long-term debt (4,000 ) (2,500 ) Long-term debt, net $ 10,958 $ 12,446 Current portion of long-term debt $ 4,000 $ 2,500 Less current portion of debt issuance costs and discount (59 ) (62 ) Current portion of long-term debt, net $ 3,941 $ 2,438 Silicon Valley Bank Debt Facilities On July 30, 2014, the Company entered into the Amended and Restated Loan and Security Agreement (the Restated LSA) with Silicon Valley Bank (the Bank), collateralized by substantially all of the Company’s assets, excluding certain intellectual property. The Restated LSA amends and restates the Loan and Security Agreement, dated as of January 5, 2009, as amended, by and between us and the Bank (Loan Agreement). Pursuant to the Restated LSA, the Bank agreed to make loans to the Company in an aggregate principal amount of up to $20.0 million, comprised of (i) a $10.0 million term loan, funded at the closing date (the Term A Loan) and (ii) subject to the achievement of a specified clinical milestone, additional term loans totaling up to $10.0 million in the aggregate, which were available until December 31, 2014 (each, a Term B Loan). On December 24, 2014, the Company elected to draw on the full $10.0 million under a Term B Loan. On July 14, 2017 (the First Amendment Effective Date), the Bank The 2017 Term Loan matures on January 1, 2022 (the Term Loan Maturity Date) and bears interest at a floating per annum rate equal to the greater of (i) 3.50% above the Prime Rate (as defined in the SVB Loan Amendment) or (ii) 7.25%; provided, however, that in no event shall such interest rate exceed 8.25%. Interest is payable on a monthly basis on the first day of each month . From August 1, 2017 through January 1, 2019 (the Interest-only Period), the Company was required to make monthly payments of interest only. In January 2019, after achievement of a product development milestone, the Company elected to extend the Interest Only Period from January 1, 2019 through and including July 31, 2019. The Company is required to repay the principal, plus monthly payments of accrued interest, in 30 equal monthly installments based on a 30-month amortization schedule. The Company’s final payment, due on the Term Loan Maturity Date, shall include all outstanding principal and accrued and unpaid interest under the 2017 Term Loan, plus a 7.5%, or $1.1 million, final payment fee. This final payment fee is accrued as interest expense over the term of the 2017 Term Loan and recorded in accrued expenses. The Company is required under its loan agreement with the Bank to maintain its deposit and securities accounts with the Bank and to comply with various operating covenants and default clauses. A breach of any of these covenants or clauses could result in a default under the agreement, which would cause all of the outstanding indebtedness under the facility to become immediately due and payable. The Company has maintained compliance with all such covenants and clauses to date. For both the three months ended March 31, 2019 and 2018, the Company recorded $0.4 million in aggregate interest expense related to the 2017 Term Loan. Warrants In connection with the funding of the Term B Loan under the Restated LSA, the Company issued the Bank and one of its affiliates fully-exercisable warrants to purchase an aggregate of 98,039 shares of the Company’s common stock (the 2014 Warrants) at an exercise price of $4.08 per share. During March 2018, a portion of the 2014 Warrants were exercised in exchange for 34,149 shares of the Company’s common stock in a cashless transaction. As of March 31, 2019, warrants to purchase 49,020 shares of the Company’s common stock remain outstanding subject to the 2014 Warrants. The 2014 Warrants expire in December 2021. In connection with the SVB Loan Amendment, the Company issued to the Bank on the First Amendment Effective Date a fully exercisable warrant (the 2017 Warrant), expiring in July 2024, to purchase up to an aggregate of 91,463 shares of the Company’s common stock, subject to adjustment, at an exercise price equal to $3.28 per share. The aggregate fair value of the 2017 Warrant was determined to be $0.2 million using the Black-Scholes option pricing model and was recorded as a debt discount on the 2017 Term Loan. This debt discount is amortized to interest expense over the term of the 2017 Term Loan using the effective interest method. The Company determined the effective interest rate of the 2017 Term Loan to be 10.2% as of the First Amendment Effective Date. During September 2018, the 2017 Warrant was fully exercised in exchange for 67,952 shares of the Company’s common stock in a cashless transaction. In connection with a prior debt agreement between the Company and the Bank in 2009, the Company issued the Bank fully exercisable warrants to purchase an aggregate of 36,074 shares of the Company’s common stock at a weighted average exercise price of $7.21 per share. During the three months ended March 31, 2019, a portion of the warrants were exercised in exchange for 1,245 shares of the Company’s common stock in a cashless transaction. As of March 31, 2019, warrants to purchase 30,769 shares of the Company’s common stock remain outstanding. These warrants expire in August 2021.

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	7. Leases The Company leases certain office and laboratory space under a non-cancelable operating lease. In May 2018, the Company amended the operating lease, extending the term of the lease through the end of 2028 and agreeing to lease additional space in the same building as its existing space. The additional space leased as a result of the amendment was considered a separate lease for accounting purposes and was recorded on the unaudited condensed consolidated balance sheets as of the lease inception date during the three months ended March 31, 2019, resulting in an increase in operating right-of-use assets of $7.7 million and an increase in the aggregate lease liability of $9.6 million. The Company can extend the term of the lease for five years after the end of 2028 at the then prevalent market rate, subject to the Company's delivery to the landlord of twelve months' prior written notice. Additionally, the Company maintains the right to terminate the lease after October 2025, subject to the Company's delivery to the landlord of twelve month's prior written notice and an early termination payment of $2.5 million. As of the date of adoption of ASC 842, the Company was not reasonably certain that it would exercise the extension option or the termination option, and as such, did not include these options in the determination of the total lease term. The lease is subject to additional variable charges for common area maintenance and other variable costs. Given the variable nature of such costs, they are recognized as expense as incurred. Further, the lease is subject to certain fixed amenities fees for the duration of the lease. These costs are considered non-lease components, which have been aggregated with the lease components into a single lease component for purposes of determining the total future lease payments. In connection with the lease, the Company has a cash-collateralized irrevocable standby letter of credit in the amount of $0.2 million. The Company does not have any additional operating or finance leases that have not yet commenced. As of March 31, 2019, future minimum payments under the operating lease are $40.6 million, which will be paid over the remaining lease term of 9.8 years. The discount rate for the operating lease liability was 8.0%, which was the Company's incremental borrowing rate at the date of adopting ASC 842. For the three months ended March 31, 2019, total operating lease cost was $1.5 million, which consisted of $0.9 million associated the straight-line recognition of fixed payments and $0.6 million associated with variable costs associated with the lease. Future minimum payments under the non-cancelable operating lease as of March 31, 2019 are as follows (in thousands): Operating Lease Payments Remaining in 2019 $ 2,422 2020 3,761 2021 3,873 2022 3,989 2023 4,109 2024 4,232 Thereafter 18,238 Total undiscounted lease payments $ 40,624 Less imputed interest (12,907 ) Total lease liability $ 27,717

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Convertible Preferred Stock And Stockholders Deficit Disclosure [Abstract]
Convertible Preferred Stock and Stockholders’ Equity	8 . Convertible Preferred Stock and Stockholders’ Equity Convertible Preferred Stock In November 2016, the Company completed a private placement of stock in which investors, certain of which are affiliated with the directors and officers of the Company, purchased convertible preferred stock and common stock of the Company (the November 2016 Placement). The Company issued 2,819,549 shares of non-voting Class A Convertible Preferred Stock (the Class A Preferred) at $13.30 per share, each of which is convertible into five shares of common stock upon certain conditions defined in the Certificate of Designation of Preferences, Rights and Limitations of the Class A Preferred filed with the Delaware Secretary of State on November 22, 2016 (the CoD). The Class A Preferred were purchased exclusively by entities affiliated with Redmile Group, LLC (collectively, Redmile). The terms of the CoD prohibited Redmile from converting the Class A Preferred into shares of the Company’s common stock if, as a result of conversion, Redmile, together with its affiliates, would own more than 9.99% of the Company’s common stock then issued and outstanding (the Redmile Percentage Limitation), which percentage could change at Redmile’s election upon 61 days’ notice to the Company to (i) any other number less than or equal to 19.99% or (ii) subject to approval of the Company’s stockholders to the extent required in accordance with the Nasdaq Global Market rules, any number in excess of 19.99%. On May 2, 2017, the Company’s stockholders approved the issuance of up to an aggregate of 14,097,745 shares of common stock upon the conversion of the outstanding shares of Class A Preferred. As a result, Redmile has the right to increase the Redmile Percentage Limitation to any percentage in excess of 19.99% at its election. The Company also issued 7,236,837 shares of common stock at $2.66 per share as part of the November 2016 Placement. Gross proceeds from the November 2016 Placement were $56.7 million, and after giving effect to costs related to placement, net proceeds were $54.9 million. The Class A Preferred are non-voting shares and have a stated par value of $0.001 per share and are convertible into five shares of the Company’s common stock at a conversion price of $2.66 per share, which was the fair value of the Company’s common stock on the date of issuance. Holders of the Class A Preferred have the same dividend rights as holders of the Company’s common stock. Additionally, the liquidation preferences of the Class A Preferred are pari passu The Company evaluated the Class A Preferred for liability or equity classification under ASC 480, Distinguishing Liabilities from Equity, The Company also evaluated the Class A Preferred in accordance with the provisions of ASC 815, Derivatives and Hedging, The issuance of convertible preferred stock could generate a beneficial conversion feature (BCF), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in-the-money) at inception because the conversion option has an effective strike price that is less than the market price of the underlying stock on the commitment date. The Class A Preferred have an effective conversion price of $2.66 per common share, which was equal to the market price of the Company’s stock on the commitment date. Therefore, no BCF was present. The Company also entered into a registration rights agreement (the Registration Rights Agreement) with certain of the purchasers in the November 2016 Placement, excluding those purchasers affiliated with the Company’s directors and officers, requiring the Company to register for the resale of the relevant shares. The Company registered all of the relevant shares issued in the November 2016 Placement for resale on a Form S-3 filed with the SEC, as required under the Registration Rights Agreement, and the registration statement was declared effective in January 2017. Stock Options and Restricted Stock Units Stock option activity under all equity and stock option plans is summarized as follows: Number of Options Weighted- Average Price Balance at December 31, 2018 6,980,581 $ 5.58 Granted 2,693,160 16.32 Cancelled (228,528 ) 10.25 Exercised (420,920 ) 3.02 Balance at March 31, 2019 9,024,293 $ 8.79 Restricted stock unit activity under all equity and stock option plans is summarized as follows: Number of Restricted Stock Units Weighted- Average Grant Date Fair Value per Share Balance at December 31, 2018 188,625 $ 4.89 Granted 490,000 16.42 Cancelled (16,000 ) 4.89 Vested — — Balance at March 31, 2019 662,625 $ 13.42 The allocation of stock-based compensation for all stock awards is as follows (in thousands): Three Months Ended March 31, 2019 2018 Research and development $ 2,183 $ 806 General and administrative 1,685 576 Total $ 3,868 $ 1,382 As of March 31, 2019, the unrecognized compensation cost related to outstanding options was $42.0 million and is expected to be recognized as expense over a weighted average period of approximately 3.5 years. As of March 31, 2019, the unrecognized compensation cost related to restricted stock units was $7.8 million which is expected to be recognized as expense over a weighted average period of approximately 3.3 years. As of January 1, 2019, the Company adopted ASU 2018-07, which aligned the guidance on share-based payments to nonemployees with that for share-based payments to employees. As such, the measurement of equity-classified nonemployee awards will be fixed at the grant date and entities are not required to remeasure nonemployee equity awards at each reporting date until such time that the measurement date is established. The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows: Three Months Ended March 31, 2019 2018 Risk-free interest rate 2.6 % 2.4 % Expected volatility 79.3 % 79.0 % Expected term (in years) 6.1 6.0 Expected dividend yield 0.0 % 0.0 % Reconciliation of Consolidated Stockholders’ Equity Accounts The following table summarizes the Company’s changes in stockholders’ equity accounts for the three months ended March 31, 2019 (in thousands, except share data): Convertible Preferred Stock Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders' Shares Amount Shares Amount Capital Loss Deficit Equity Balance at December 31, 2018 2,819,549 $ 3 64,693,681 $ 65 $ 445,799 $ (2 ) $ (285,396 ) $ 160,469 Exercise of stock options, net of issuance costs — — 420,920 — 1,258 — — 1,258 Issuance of common stock upon cashless warrant exercise — — 1,245 — — — — — Stock-based compensation — — — — 3,868 — — 3,868 Unrealized gain on short-term investments — — — — — 2 — 2 Net loss — — — — — — (19,760 ) (19,760 ) Balance at March 31, 2019 2,819,549 $ 3 65,115,846 $ 65 $ 450,925 $ — $ (305,156 ) $ 145,837 The following table summarizes the Company’s changes in stockholders’ equity accounts for the three months ended March 31, 2018 (in thousands, except share data): Convertible Preferred Stock Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders' Shares Amount Shares Amount Capital Loss Deficit Equity Balance at December 31, 2017 2,819,549 $ 3 52,648,601 $ 53 $ 295,934 $ (3 ) $ (218,798 ) $ 77,189 Exercise of stock options, net of issuance costs — — 174,984 — 606 — — 606 Issuance of common stock upon cashless warrant exercise — — 34,149 — — — — — Stock-based compensation — — — — 1,382 — — 1,382 Issuance costs from public offering of common stock — — — — (37 ) — — (37 ) Unrealized loss on short-term investments — — — — — (10 ) — (10 ) Net loss — — — — — — (14,135 ) (14,135 ) Balance at March 31, 2018 2,819,549 $ 3 52,857,734 $ 53 $ 297,885 $ (13 ) $ (232,933 ) $ 64,995

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Public Equity Offerings	Public Equity Offerings In September 2018, the Company completed a public offering of common stock in which investors, certain of which are affiliated with the directors of the Company, purchased 10,648,149 shares of its common stock at a price of $13.50 per share under a shelf registration statement. Gross proceeds from the offering were $143.8 million, and, after giving effect to $8.9 million of costs related to the offering, net proceeds were $134.9 million. In December 2017, the Company completed a public offering of common stock in which investors purchased 10,953,750 shares of its common stock at a price of $4.20 per share under a shelf registration statement. Gross proceeds from the offering were $46.0 million, and, after giving effect to $3.0 million of costs related to the offering (of which $0.3 million was paid during the three months ended March 31, 2018), net proceeds were $43.0 million.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Therapeutics Ltd., incorporated in the United Kingdom, Fate Therapeutics, B.V., incorporated in the Netherlands, and Tfinity Therapeutics, Inc., incorporated in the United States. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amount shown in the unaudited condensed consolidated statements of cash flows as of March 31, 2019 (in thousands): Three Months Ended March 31, 2019 Cash and cash equivalents $ 183,033 Restricted cash 227 Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statement of cash flows $ 183,260 Amounts included in restricted cash represent security deposits required to secure the Company’s credit card limit and its facilities lease.
Investments	Investments Investments are accounted for as available-for-sale securities and are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of investments classified as available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on investments classified as available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. The interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements and accompanying notes for the fiscal year ended December 31, 2018, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed by the Company with the SEC on March 5, 2019. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position and its results of operations and comprehensive loss and its cash flows for the periods presented. The results for the three months ended March 31, 2019 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. A customer is a party that has entered into a contract with the Company, where the purpose of the contract is to obtain a product or a service that is an output of the Company’s ordinary activities in exchange for consideration. To be considered a contract, (i) the contract must be approved (in writing, orally, or in accordance with other customary business practices), (ii) each party’s rights regarding the product product product A performance obligation is defined as a promise to transfer a product The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation in an amount that reflects the consideration the Company is entitled to receive in exchange for satisfying each distinct performance obligation. For each distinct performance obligation, revenue is recognized when (or as) the Company transfers control of the product or the service applicable to such performance obligation. In those instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until (or as) the Company satisfies such performance obligation. In those instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is recorded as accounts receivable. The Company expenses incremental costs of obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract.
Leases	Leases Effective January 1, 2019, the Company determines if a contract contains a lease at the inception of the contract. The Company currently has leases related to its facilities leased for office and laboratory space, which are classified as operating leases. These leases result in operating right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities in the condensed consolidated balance sheets. The Company does not have any financing leases. Leases with a term of 12 months or less are considered short-term and a ROU asset and lease obligation are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term. ROU assets represent the right to use an underlying asset for the lease term and the lease liabilities represent an obligation to make lease payments arising from the lease, measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the life of the lease term. To determine the present value, the implicit rate is used when readily determinable. For those leases where the implicit rate is not provided, the Company determines an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The operating lease ROU assets also include any prepaid lease payments made and any other indirect costs and excludes any lease incentives received. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company aggregates all lease and non-lease components for each class of underlying assets into a single lease component .
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model. The fair value of restricted stock units is based on the closing price of the Company’s common stock as reported on The Nasdaq Global Market on the date of grant. The Company recognizes forfeitures for all awards as such forfeitures occur.
Convertible Preferred Stock	Convertible Preferred Stock The Company applies the relevant accounting standards to distinguish liabilities from equity when assessing the classification and measurement of preferred stock. Preferred shares subject to mandatory redemptions are considered liabilities and measured at fair value. Conditionally redeemable preferred shares are considered temporary equity. All other preferred shares are considered as stockholders’ equity. The Company applies the relevant accounting standards for derivatives and hedging (in addition to distinguishing liabilities from equity) when accounting for hybrid contracts that contain conversion options. Conversion options must be bifurcated from the host instruments and accounted for as free-standing financial instruments according to certain criteria. These criteria include circumstances when (i) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable accounting principles with changes in fair value reported in earnings as they occurred, and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently measured at fair value at each reporting date, with the changes in fair value reported in earnings.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non‑owner sources. Other comprehensive loss includes unrealized gains and losses on investments classified as available-for-sale securities, which was the only difference between net loss and comprehensive loss for the applicable periods.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Dilutive common stock equivalents for the periods presented include convertible preferred stock, warrants for the purchase of common stock, and common stock options and restricted stock units outstanding under the Company’s stock option and incentive plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. For the three months ended March 31, 2019, the Company realized a net loss of $19.8 million. Shares of potentially dilutive securities totaled 23.9 million for the three months ended March 31, 2019, including 14.1 million shares associated with a hypothetical conversion of all outstanding shares of the Company’s Class A convertible preferred stock, and an aggregate of 9.7 million shares of common stock issuable upon the exercise of outstanding stock options and the settlement of outstanding restricted stock units. For the three months ended March 31, 2018, the Company realized a net loss of $14.1 million. Shares of potentially dilutive securities totaled 22.0 million for the three months ended March 31, 2018, including 14.1 million shares associated with a hypothetical conversion of all outstanding shares of the Company’s Class A convertible preferred stock, and an aggregate of 7.7 million shares of common stock issuable upon the exercise of outstanding stock options and the settlement of outstanding restricted stock units.
Going Concern Assessment	Going Concern Assessment Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07. ASU 2018-07 expands the scope of Accounting Standards Codification (ASC) 718, Compensation- Stock Compensation, In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) The Company adopted the standard effective January 1, 2019 using the optional transition method as detailed in ASU 2018-11, which resulted in an increase in operating right-of-use assets of $16.6 million and an increase in total liabilities of $18.2 million on the unaudited condensed consolidated balance sheet as of the effective date. There was not a material impact to the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2019 as a result of the adoption of ASU 2016-02. There was no impact to the unaudited condensed consolidated financial statements for the prior periods presented due to the transition method elected. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed the Company to carry forward the historical lease classification. Additionally, the Company elected the hindsight provision for determining the lease term and elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component. Recently Issued Accounting Pronouncements In November 2018, the FASB issued ASU 2018-18, which clarifies the interaction between ASC Topic 808, Collaborative Arrangements Revenue from Contracts with Customers In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments In August 2018, the FASB issued ASU No. 2018-13 (ASU 2018-13). ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, amends the disclosure requirements in 820 by adding, changing, or removing certain disclosures. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. The Company believes that the adoption of this guidance will not have a material impact on the Company’s consolidated financial statements.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amount shown in the unaudited condensed consolidated statements of cash flows as of March 31, 2019 (in thousands): Three Months Ended March 31, 2019 Cash and cash equivalents $ 183,033 Restricted cash 227 Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statement of cash flows $ 183,260

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2019
Short Term Investments [Abstract]
Summary of Investments	The following table summarizes the Company’s investments accounted for as available-for-sale securities as of December 31, 2018 (in thousands): Maturity (in years) Amortized Cost Unrealized Losses Unrealized Gains Estimated Fair Value December 31, 2018 U.S. Treasury debt securities 1 or less 10,495 (2 ) — 10,493 Total $ 10,495 $ (2 ) $ — $ 10,493

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring Basis	The following table presents the Company’s assets which were measured at fair value on a recurring basis as of March 31, 2019 and December 31, 2018 (in thousands): Fair Value Measurements at Reporting Date Using Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) As of March 31, 2019: Cash equivalents $ 183,033 $ 183,033 $ — $ — Total $ 183,033 $ 183,033 $ — $ — As of December 31, 2018: Cash equivalents $ 190,514 $ 190,514 $ — $ — U.S. Treasury debt securities 10,493 10,493 — — Total $ 201,007 $ 201,007 $ — $ —

Accrued Expenses and Long-Ter_2

Accrued Expenses and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Accrued Expenses And Long Term Debt Disclosure [Abstract]
Schedule of accrued expenses	Current accrued expenses consist of the following (in thousands): March 31, 2019 December 31, 2018 Accrued payroll and other employee benefits $ 1,901 $ 2,938 Accrued clinical trial related costs 4,462 4,729 Accrued other 3,587 3,259 Current accrued expenses $ 9,950 $ 10,926
Schedule of long-term debt and unamortized discount balances	Long-term debt and unamortized discount balances are as follows (in thousands): March 31, 2019 December 31, 2018 Long-term debt $ 15,000 $ 15,000 Less debt issuance costs and discount, net of current portion (42 ) (54 ) Long-term debt, net of long-term portion of debt issuance costs and discount 14,958 14,946 Less current portion of long-term debt (4,000 ) (2,500 ) Long-term debt, net $ 10,958 $ 12,446 Current portion of long-term debt $ 4,000 $ 2,500 Less current portion of debt issuance costs and discount (59 ) (62 ) Current portion of long-term debt, net $ 3,941 $ 2,438

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of Future Minimum Payments Under Non-cancelable Operating Lease	Future minimum payments under the non-cancelable operating lease as of March 31, 2019 are as follows (in thousands): Operating Lease Payments Remaining in 2019 $ 2,422 2020 3,761 2021 3,873 2022 3,989 2023 4,109 2024 4,232 Thereafter 18,238 Total undiscounted lease payments $ 40,624 Less imputed interest (12,907 ) Total lease liability $ 27,717

Convertible Preferred Stock a_2

Convertible Preferred Stock and Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract]
Summary of stock option activity under the Plan	Stock option activity under all equity and stock option plans is summarized as follows: Number of Options Weighted- Average Price Balance at December 31, 2018 6,980,581 $ 5.58 Granted 2,693,160 16.32 Cancelled (228,528 ) 10.25 Exercised (420,920 ) 3.02 Balance at March 31, 2019 9,024,293 $ 8.79
Summary of restricted stock unit activity under the Plan	Restricted stock unit activity under all equity and stock option plans is summarized as follows: Number of Restricted Stock Units Weighted- Average Grant Date Fair Value per Share Balance at December 31, 2018 188,625 $ 4.89 Granted 490,000 16.42 Cancelled (16,000 ) 4.89 Vested — — Balance at March 31, 2019 662,625 $ 13.42
Schedule of allocation of stock-based compensation for all stock awards	The allocation of stock-based compensation for all stock awards is as follows (in thousands): Three Months Ended March 31, 2019 2018 Research and development $ 2,183 $ 806 General and administrative 1,685 576 Total $ 3,868 $ 1,382
Schedule of weighted-average assumptions used to determine the fair value of employee and nonemployee stock option grants	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows: Three Months Ended March 31, 2019 2018 Risk-free interest rate 2.6 % 2.4 % Expected volatility 79.3 % 79.0 % Expected term (in years) 6.1 6.0 Expected dividend yield 0.0 % 0.0 %
Summary of changes in stockholders' equity	The following table summarizes the Company’s changes in stockholders’ equity accounts for the three months ended March 31, 2019 (in thousands, except share data): Convertible Preferred Stock Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders' Shares Amount Shares Amount Capital Loss Deficit Equity Balance at December 31, 2018 2,819,549 $ 3 64,693,681 $ 65 $ 445,799 $ (2 ) $ (285,396 ) $ 160,469 Exercise of stock options, net of issuance costs — — 420,920 — 1,258 — — 1,258 Issuance of common stock upon cashless warrant exercise — — 1,245 — — — — — Stock-based compensation — — — — 3,868 — — 3,868 Unrealized gain on short-term investments — — — — — 2 — 2 Net loss — — — — — — (19,760 ) (19,760 ) Balance at March 31, 2019 2,819,549 $ 3 65,115,846 $ 65 $ 450,925 $ — $ (305,156 ) $ 145,837 The following table summarizes the Company’s changes in stockholders’ equity accounts for the three months ended March 31, 2018 (in thousands, except share data): Convertible Preferred Stock Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders' Shares Amount Shares Amount Capital Loss Deficit Equity Balance at December 31, 2017 2,819,549 $ 3 52,648,601 $ 53 $ 295,934 $ (3 ) $ (218,798 ) $ 77,189 Exercise of stock options, net of issuance costs — — 174,984 — 606 — — 606 Issuance of common stock upon cashless warrant exercise — — 34,149 — — — — — Stock-based compensation — — — — 1,382 — — 1,382 Issuance costs from public offering of common stock — — — — (37 ) — — (37 ) Unrealized loss on short-term investments — — — — — (10 ) — (10 ) Net loss — — — — — — (14,135 ) (14,135 ) Balance at March 31, 2018 2,819,549 $ 3 52,857,734 $ 53 $ 297,885 $ (13 ) $ (232,933 ) $ 64,995

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Jan. 01, 2019
Organization and summary of significant accounting policies
Net loss			$ (19,760)	$ (14,135)
Potentially dilutive securities (in shares)			23,900,000	22,000,000
Common stock issuable upon the exercise of outstanding options and restricted stock			9,700,000	7,700,000
Increase in operating right-of-use assets			$ 23,955
Increase in liabilities			$ 27,717
ASU 2016-02 | Difference Between Lease Guidance in Effect Before and After Topic 842
Organization and summary of significant accounting policies
Increase in operating right-of-use assets					$ 18,200
Increase in liabilities					$ 16,600
Class A Convertible Preferred Stock
Organization and summary of significant accounting policies
Shares associated with a hypothetical conversion of convertible preferred stock			14,100,000	14,100,000
Maximum
Organization and summary of significant accounting policies
Short-term leases term excluded from calculation of ROU and lease liabilities			12 months
September 2018 Public Equity Offering
Organization and summary of significant accounting policies
Shares sold	10,648,149
Share issue price (in dollars per share)	$ 13.50
Gross proceeds from issuance of shares	$ 143,800
Net proceeds from issuance of shares after related cash costs	134,900
Costs related to equity offering	$ 8,900
December 2017 Public Equity Offering
Organization and summary of significant accounting policies
Shares sold		10,953,750
Share issue price (in dollars per share)		$ 4.20
Gross proceeds from issuance of shares		$ 46,000
Net proceeds from issuance of shares after related cash costs		43,000
Costs related to equity offering		$ 3,000
Costs related to equity offering paid				$ 300

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Cash and cash equivalents	$ 183,033	$ 190,514
Restricted cash	227
Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statement of cash flows	$ 183,260	$ 190,741	$ 33,034	$ 89,074

Collaboration and License Agr_2

Collaboration and License Agreements (Details) - USD ($)	May 04, 2019	Sep. 14, 2018	Sep. 11, 2018	May 15, 2018	Oct. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Collaboration agreement
Research and development						$ 17,728,000	$ 11,476,000
Collaboration contract asset						1,851,000		$ 1,958,000
Revenue recognized						2,632,000	1,026,000
Aggregate deferred revenue, current						$ 6,576,000		$ 7,588,000
Common stock issued						65,115,846		64,693,681
Ono Pharmaceutical Co. Ltd
Collaboration agreement
Aggregate research and development fees payments receivable		$ 20,000,000
Payments for research and development fees					$ 5,000,000
Collaborative arrangement potential additional milestones		40,000,000
Non-refundable upfront payments recorded as deferred revenue		$ 10,000,000
Recognition period of deferred revenue		4 years
Collaborative arrangement annual payments receivable recorded as deferred revenue					$ 5,000,000
Ono Pharmaceutical Co. Ltd | Candidate 2
Collaboration agreement
Percentage of reduction on milestone payments		50.00%
Ono Pharmaceutical Co. Ltd | Maximum | Candidate 1
Collaboration agreement
Aggregate milestone payments		$ 285,000,000
Ono Pharmaceutical Co. Ltd | Maximum | Candidate 2
Collaboration agreement
Aggregate milestone payments		895,000,000
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement
Collaboration agreement
Upfront non-refundable, non-creditable payment receivable		10,000,000
Transaction price of the agreement		30,000,000
Research and development		$ 20,000,000				$ 100,000
Sub license consideration payable						2,000,000
Asset corresponding to sub license consideration						2,000,000
Collaboration contract asset						1,900,000
Revenue recognized						1,600,000
Estimated research payments received under agreement						1,100,000
Proceeds from non refundable upfront fee						500,000
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement | Research services
Collaboration agreement
Revenue recognized						12,800,000
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement | Upfront Fee
Collaboration agreement
Revenue recognized						6,400,000
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement | Minimum
Collaboration agreement
Profits and losses sharing percentage		50.00%
Juno Therapeutics, Inc | Collaborative Arrangement
Collaboration agreement
Revenue recognized						1,000,000	1,000,000
Aggregate deferred revenue, current						200,000
Revenue recognize from previous deferred revenue						500,000
Juno Therapeutics, Inc | Collaborative Arrangement | Subsequent Event
Collaboration agreement
Research term	4 years
Collaboration agreement expiration date	May 4, 2019
Agreement to terminate upon the receipt of research payment	$ 200,000
Collaborative additional research payment	$ 0
Juno Therapeutics, Inc | Collaborative Arrangement | Research services
Collaboration agreement
Revenue recognized						500,000	500,000
Juno Therapeutics, Inc | Collaborative Arrangement | Upfront Fee and Equity Premium
Collaboration agreement
Revenue recognized						500,000	$ 500,000
MSK | Amended MSK License
Collaboration agreement
Research and development						5,300,000
Common stock issued				500,000
Upfront cash payment				$ 500,000		4,800,000
Issuance of common stock for license agreements						500,000
Gladstone | Gladstone License Agreement
Collaboration agreement
Aggregate milestone payments			$ 1,900,000
Research and development						1,400,000
Common stock issued			100,000
Upfront cash payment			$ 100,000			100,000
Issuance of common stock for license agreements						$ 1,300,000

California Institute For Rege_2

California Institute For Regenerative Medicine Award (Details) $ in Millions	Apr. 05, 2018USD ($)Disbursement	Jun. 30, 2019	Jan. 31, 2019USD ($)	Mar. 31, 2019USD ($)
Award from California institute for regenerative medicine
Period to treat award as grant, if award not treated as loan				10 years
California Institute for Regenerative Medicine
Award from California institute for regenerative medicine
Receipt of first disbursement under the Award | $				$ 3.5
California Institute for Regenerative Medicine | LIBOR | Scenario, Forecast
Award from California institute for regenerative medicine
Award considered as a loan, interest rate		7.00%
California Institute for Regenerative Medicine | Loan Repayment Period One | Scenario, Forecast
Award from California institute for regenerative medicine
Repayment percentage of award amount		60.00%
California Institute for Regenerative Medicine | Loan Repayment Period Two | Scenario, Forecast
Award from California institute for regenerative medicine
Repayment percentage of award amount		80.00%
California Institute for Regenerative Medicine | Loan Repayment Period Three | Scenario, Forecast
Award from California institute for regenerative medicine
Repayment percentage of award amount		100.00%
California Institute for Regenerative Medicine | Loan Repayment Period Four | Scenario, Forecast
Award from California institute for regenerative medicine
Repayment percentage of award amount		100.00%
California Institute for Regenerative Medicine | FT516
Award from California institute for regenerative medicine
Award agreement executed date	Apr. 5, 2018
Award for first-in-human clinical trial | $	$ 4
Number of disbursements | Disbursement	5
Number of disbursement receivable upon the execution of the award | Disbursement	1
Number of disbursements receivable based on completion of certain operating milestones | Disbursement	4
Estimated project start date	Apr. 1, 2018
Estimated project end date	Jun. 30, 2019
Addtional amount available for funding under award | $			$ 0.5

Investments (Details)

Investments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, impairment	$ 0	$ 0
Available-for-sale securities, realized gains (losses) on sales	$ 0	$ 0
U.S. Treasury debt securities
Schedule Of Available For Sale Securities [Line Items]
Short term investments, maturity start range	3 months
Short term investments, maturity end range	12 months

Investments (Details 2)

Investments (Details 2) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 10,495
Unrealized Losses	(2)
Estimated Fair Value	$ 10,493
U.S. Treasury debt securities
Schedule Of Available For Sale Securities [Line Items]
Maturity (in years)	1 or less
Amortized Cost	$ 10,495
Unrealized Losses	(2)
Estimated Fair Value	$ 10,493

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
U.S. Treasury debt securities		$ 10,493
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	$ 183,033	190,514
Total	183,033	201,007
Fair Value Measurements Recurring | U.S. Treasury debt securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
U.S. Treasury debt securities		10,493
Fair Value Measurements Recurring | Quoted prices in Active Market for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	183,033	190,514
Total	$ 183,033	201,007
Fair Value Measurements Recurring | Quoted prices in Active Market for Identical Assets (Level 1) | U.S. Treasury debt securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
U.S. Treasury debt securities		$ 10,493

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 2) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer of assets from level 1 to level 2	$ 0
Transfer of assets from level 2 to level 1	0
Transfer of liabilities from level 1 to level 2	0
Transfer of liabilities from level 2 to level 1	0
Fair Value Measurements Nonrecurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-financial assets	0
Non-financial liabilities	0
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-financial assets	183,033,000	$ 201,007,000
Liabilities measured at fair value	$ 0	$ 0

Accrued Expenses and Long-Ter_3

Accrued Expenses and Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current accrued expenses
Accrued payroll and other employee benefits	$ 1,901	$ 2,938
Accrued clinical trial related costs	4,462	4,729
Accrued other	3,587	3,259
Current accrued expenses	$ 9,950	$ 10,926

Accrued Expenses and Long-Ter_4

Accrued Expenses and Long-Term Debt (Details 2) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Long-term debt	$ 15,000	$ 15,000
Less debt issuance costs and discount, net of current portion	(42)	(54)
Long-term debt, net of long-term portion of debt issuance costs and discount	14,958	14,946
Less current portion of long-term debt	(4,000)	(2,500)
Long-term debt, net	10,958	12,446
Current portion of long-term debt	4,000	2,500
Less current portion of debt issuance costs and discount	(59)	(62)
Current portion of long-term debt, net	$ 3,941	$ 2,438

Accrued Expenses and Long-Ter_5

Accrued Expenses and Long-Term Debt (Details 3) - USD ($)	Jul. 14, 2017	Sep. 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 24, 2014	Jul. 30, 2014
Amended And Restated Loan And Security Agreement | Warrant
Current accrued expenses
Warrants to purchase shares of common stock issued on conversion			36,074
Exercise price (in dollars per share)			$ 7.21
Common stock shares received upon exercise of warrant			1,245
Warrants expiration date			2021-08
Amended And Restated Loan And Security Agreement | Warrant | Warrants Expiration Period December 2021
Current accrued expenses
Warrants to purchase shares of common stock issued on conversion			30,769
Amended And Restated Loan And Security Agreement | Maximum | Silicon Valley Bank Debt Facilities
Current accrued expenses
Principal amount						$ 20,000,000
Amended And Restated Loan And Security Agreement | Term A Loan | Silicon Valley Bank Debt Facilities
Current accrued expenses
Principal amount						10,000,000
Amended And Restated Loan And Security Agreement | Term B Loan | 2014 Warrants
Current accrued expenses
Warrants to purchase shares of common stock issued on conversion			98,039
Exercise price (in dollars per share)			$ 4.08
Common stock shares received upon exercise of warrant			34,149
Warrants expiration date			2021-12
Amended And Restated Loan And Security Agreement | Term B Loan | 2014 Warrants | Warrants Expiration Period December 2021
Current accrued expenses
Warrants to purchase shares of common stock issued on conversion			49,020
Amended And Restated Loan And Security Agreement | Term B Loan | Maximum | Silicon Valley Bank Debt Facilities
Current accrued expenses
Principal amount						$ 10,000,000
Amended And Restated Loan And Security Agreement | Term B Loan Tranche 1 | Minimum | Silicon Valley Bank Debt Facilities
Current accrued expenses
Principal amount					$ 10,000,000
SVB Loan Amendment | 2017 Term Loan
Current accrued expenses
Principal amount	$ 15,000,000
Cash proceeds from remaining portion of debt	$ 7,500,000
Debt instrument, maturity date	Jan. 1, 2022
Debt instrument, variable rate description			The 2017 Term Loan matures on January 1, 2022 (the Term Loan Maturity Date) and bears interest at a floating per annum rate equal to the greater of (i) 3.50% above the Prime Rate (as defined in the SVB Loan Amendment) or (ii) 7.25%; provided, however, that in no event shall such interest rate exceed 8.25%.
Debt instrument, interest payment terms			Interest is payable on a monthly basis on the first day of each month.
Debt instrument, frequency of periodic payment			monthly
Interest rate (as a percent)			8.25%
Debt instrument interest only payment period			August 1, 2017 through January 1, 2019
Debt instrument extended interest only payment period			January 1, 2019 through and including July 31, 2019
Final payment fee			7.50%
Final payment fee (amounts in dollars)			$ 1,100,000
Aggregate interest expense			$ 400,000	$ 400,000
Effective interest rate	10.20%
SVB Loan Amendment | 2017 Term Loan | 2017 Warrant
Current accrued expenses
Exercise price (in dollars per share)	$ 3.28
Common stock shares received upon exercise of warrant		67,952
Warrants expiration date	2024-07
Fair values of warrants issued	$ 200,000
SVB Loan Amendment | 2017 Term Loan | Product Development Milestone Achievement
Current accrued expenses
Number of equal monthly installments to repay principal and accrued interest	30 months
SVB Loan Amendment | 2017 Term Loan | Maximum
Current accrued expenses
Debt instrument, floating rate	8.25%
SVB Loan Amendment | 2017 Term Loan | Maximum | 2017 Warrant
Current accrued expenses
Warrants to purchase shares of common stock issued on conversion	91,463
SVB Loan Amendment | 2017 Term Loan | Minimum
Current accrued expenses
Debt instrument, floating rate	7.25%
SVB Loan Amendment | 2017 Term Loan | Minimum | Prime Rate
Current accrued expenses
Debt instrument, floating rate	3.50%

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	May 31, 2018	Mar. 31, 2019
Leases [Abstract]
Lease extended term	2028
Lessee, operating lease, existence of option to extend		true
Lessee, operating lease, option to extend		The Company can extend the term of the lease for five years after the end of 2028 at the then prevalent market rate, subject to the Company's delivery to the landlord of twelve months' prior written notice.
Additional operating lease term	5 years
Lessee, operating lease, existence of option to terminate		true
Early termination payment description		the Company maintains the right to terminate the lease after October 2025, subject to the Company's delivery to the landlord of twelve month's prior written notice and an early termination payment of $2.5 million.
Lease expiration period	2025-10
Payment for early termination of lease	$ 2,500
Cash-collateralized irrevocable standby letter of credit	$ 200
Changes in operating right-of-use assets		$ 7,700
Changes in operating lease liability		9,600
Future minimum payments under the operating lease		$ 40,624
Remaining lease term		9 years 9 months 18 days
Operating lease liability, discount rate		8.00%
Operating lease cost		$ 1,500
Straight-line recognition of fixed payments		900
Variable lease cost		$ 600

Leases (Details 2)

Leases (Details 2) $ in Thousands	Mar. 31, 2019USD ($)
Operating Lease Liabilities Payments Due [Abstract]
Remaining in 2019	$ 2,422
2020	3,761
2021	3,873
2022	3,989
2023	4,109
2024	4,232
Thereafter	18,238
Total undiscounted lease payments	40,624
Less imputed interest	(12,907)
Total lease liability	$ 27,717

Convertible Preferred Stock a_3

Convertible Preferred Stock and Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Nov. 30, 2016	Mar. 31, 2019	Dec. 31, 2018	May 02, 2017
Convertible preferred stock
Preferred stock, par value (in dollars per share)		$ 0.001	$ 0.001
Employee And Non Employee Stock Option
Convertible preferred stock
Unrecognized compensation cost related to outstanding options		$ 42
Expected recognition weighted average period of unrecognized compensation cost		3 years 6 months
Restricted Stock Units (RSUs)
Convertible preferred stock
Expected recognition weighted average period of unrecognized compensation cost		3 years 3 months 18 days
Unrecognized compensation cost related to unvested restricted shares		$ 7.8
Non-Voting Class A Preferred Stock
Convertible preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001
Conversion price	$ 2.66	$ 2.66
Non-Voting Class A Preferred Stock | Redmile Group, LLC and Affiliates
Convertible preferred stock
Terms of conversion		The Class A Preferred were purchased exclusively by entities affiliated with Redmile Group, LLC (collectively, Redmile). The terms of the CoD prohibited Redmile from converting the Class A Preferred into shares of the Company’s common stock if, as a result of conversion, Redmile, together with its affiliates, would own more than 9.99% of the Company’s common stock then issued and outstanding (the Redmile Percentage Limitation), which percentage could change at Redmile’s election upon 61 days’ notice to the Company to (i) any other number less than or equal to 19.99% or (ii) subject to approval of the Company’s stockholders to the extent required in accordance with the Nasdaq Global Market rules, any number in excess of 19.99%. On May 2, 2017, the Company’s stockholders approved the issuance of up to an aggregate of 14,097,745 shares of common stock upon the conversion of the outstanding shares of Class A Preferred. As a result, Redmile has the right to increase the Redmile Percentage Limitation to any percentage in excess of 19.99% at its election.
Non-Voting Class A Preferred Stock | Maximum
Convertible preferred stock
Number of shares to be issued upon conversion				14,097,745
Non-Voting Class A Preferred Stock | Maximum | Redmile Group, LLC and Affiliates
Convertible preferred stock
Percentage of common stock ownership upon preferred stock conversion	9.99%
Preferred shares converted into common stock percentage of ownership change upon notice	19.99%
Private Placement | Common Stock
Convertible preferred stock
Share issue price (in dollars per share)	$ 2.66
Common stock issued	7,236,837
Net proceeds from issuance of shares after related cash costs	$ 54.9
Gross proceeds from issuance of shares	$ 56.7
Private Placement | Non-Voting Class A Preferred Stock
Convertible preferred stock
Preferred stock, issued shares	2,819,549
Share issue price (in dollars per share)	$ 13.30
Number of shares to be issued upon conversion	5

Convertible Preferred Stock a_4

Convertible Preferred Stock and Stockholders' Equity (Details 2) - Employee And Non Employee Stock Option	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Options
Balance at the beginning of the period | shares	6,980,581
Granted | shares	2,693,160
Cancelled | shares	(228,528)
Exercised | shares	(420,920)
Balance at the end of the period | shares	9,024,293
Weighted-Average Price
Balance at the beginning of the period | $ / shares	$ 5.58
Granted | $ / shares	16.32
Cancelled | $ / shares	10.25
Exercised | $ / shares	3.02
Balance at the end of the period | $ / shares	$ 8.79

Convertible Preferred Stock a_5

Convertible Preferred Stock and Stockholders' Equity (Details 3) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Restricted Stock Units
Balance at the beginning of the period | shares	188,625
Granted | shares	490,000
Cancelled | shares	(16,000)
Balance at the end of the period | shares	662,625
Weighted-Average Grant Date Fair Value per Share
Balance at the beginning of the period | $ / shares	$ 4.89
Granted | $ / shares	16.42
Cancelled | $ / shares	4.89
Balance at the end of the period | $ / shares	$ 13.42

Convertible Preferred Stock a_6

Convertible Preferred Stock and Stockholders' Equity (Details 4) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Convertible preferred stock
Total stock-based compensation expense	$ 3,868	$ 1,382
Research And Development
Convertible preferred stock
Total stock-based compensation expense	2,183	806
General And Administrative
Convertible preferred stock
Total stock-based compensation expense	$ 1,685	$ 576

Convertible Preferred Stock a_7

Convertible Preferred Stock and Stockholders' Equity (Details 5) - Employee And Non Employee Stock Option	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Weighted-average assumptions to determine fair value of stock options
Risk-free interest rate	2.60%	2.40%
Expected volatility	79.30%	79.00%
Expected term (in years)	6 years 1 month 6 days	6 years
Expected dividend yield	0.00%	0.00%

Convertible Preferred Stock a_8

Convertible Preferred Stock and Stockholders' Equity (Details 6) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Class Of Stock [Line Items]
Beginning balance	$ 160,469	$ 77,189
Exercise of stock options, net of issuance costs	1,258	606
Stock-based compensation	3,868	1,382
Unrealized gain (loss) on short-term investments	2	(10)
Issuance costs from public offering of common stock		(37)
Net loss	(19,760)	(14,135)
Ending balance	145,837	64,995
Class A Convertible Preferred Shares
Class Of Stock [Line Items]
Beginning balance	$ 3	$ 3
Balance (in shares)	2,819,549	2,819,549
Ending balance	$ 3	$ 3
Balance (in shares)	2,819,549	2,819,549
Common Stock
Class Of Stock [Line Items]
Beginning balance	$ 65	$ 53
Balance (in shares)	64,693,681	52,648,601
Exercise of stock options, net of issuance costs (in shares)	420,920	174,984
Issuance of common stock upon cashless warrant exercises (in shares)	1,245	34,149
Ending balance	$ 65	$ 53
Balance (in shares)	65,115,846	52,857,734
Additional Paid In Capital
Class Of Stock [Line Items]
Beginning balance	$ 445,799	$ 295,934
Exercise of stock options, net of issuance costs	1,258	606
Stock-based compensation	3,868	1,382
Issuance costs from public offering of common stock		(37)
Ending balance	450,925	297,885
Accumulated Other Comprehensive Loss
Class Of Stock [Line Items]
Beginning balance	(2)	(3)
Unrealized gain (loss) on short-term investments	2	(10)
Ending balance		(13)
Accumulated Deficit
Class Of Stock [Line Items]
Beginning balance	(285,396)	(218,798)
Net loss	(19,760)	(14,135)
Ending balance	$ (305,156)	$ (232,933)